TUMOR BLOOD TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Market Segmentation

• Biomarker Type Insights (Revenue, USD Bn, 2021 - 2033)

  • Circulating Tumor DNA (ctDNA)
  • Circulating Tumor Cells (CTCs)
  • Extracellular Vesicles (EVs) / Exosomes
  • Other Cell-Free Nucleic Acids

• Technology Insights (Revenue, USD Bn, 2021 - 2033)

  • Polymerase Chain Reaction (PCR)-Based Testing
  • Next-Generation Sequencing (NGS)
  • Microarray-Based Testing
  • Mass Spectrometry
  • Immunoassays

• Clinical Application Insights (Revenue, USD Bn, 2021 - 2033)

  • Early Detection/Cancer Screening
  • Diagnosis
  • Therapy Selection
  • Treatment Monitoring
  • Minimal Residual Disease (MRD) Detection
  • Recurrence Monitoring/Prognosis

• Cancer Type Insights (Revenue, USD Bn, 2021 - 2033)

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)

• End User Insights (Revenue, USD Bn, 2021 - 2033)

  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies

• Regional Insights (Revenue, USD Bn, 2021 - 2033)

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa